Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies

Armin Ghobadi; Jack H. Landmann; Alun Carter; Matthew L. Cooper; Mehmet Emrah Selli; Jufang Chang; Matthew Baker; Christopher A. Miller; Francesca Ferraro; David Y. Chen; Amanda M. Smith; Taylor A. LaValle; Eric J. Duncavage; Justin Chou; Victor Tam; Joseph M. Benoun; Jenny Nater; Nathalie Scholler; Francesca Milletti; Remus Vezan; Adrian Bot; John M. Rossi; Nathan Singh

doi:10.1182/bloodadvances.2022007705

Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies

Armin Ghobadi, Jack H. Landmann, Alun Carter, Matthew L. Cooper, Mehmet Emrah Selli, Jufang Chang, Matthew Baker, Christopher A. Miller, Francesca Ferraro, David Y. Chen, Amanda M. Smith, Taylor A. LaValle, Eric J. Duncavage, Justin Chou, Victor Tam, Joseph M. Benoun, Jenny Nater, Nathalie Scholler, Francesca Milletti, Remus VezanAdrian Bot, John M. Rossi, Nathan Singh

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	5634-5640
Number of pages	7
Journal	Blood Advances
Volume	6
Issue number	20
DOIs	https://doi.org/10.1182/bloodadvances.2022007705
State	Published - Oct 25 2022

Access to Document

10.1182/bloodadvances.2022007705

Cite this

Ghobadi, A., Landmann, J. H., Carter, A., Cooper, M. L., Selli, M. E., Chang, J., Baker, M., Miller, C. A., Ferraro, F., Chen, D. Y., Smith, A. M., LaValle, T. A., Duncavage, E. J., Chou, J., Tam, V., Benoun, J. M., Nater, J., Scholler, N., Milletti, F., ... Singh, N. (2022). Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies. Blood Advances, 6(20), 5634-5640. https://doi.org/10.1182/bloodadvances.2022007705

@article{597eb9309ab04e6085e52a8478b3c5ad,

title = "Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies",

author = "Armin Ghobadi and Landmann, {Jack H.} and Alun Carter and Cooper, {Matthew L.} and Selli, {Mehmet Emrah} and Jufang Chang and Matthew Baker and Miller, {Christopher A.} and Francesca Ferraro and Chen, {David Y.} and Smith, {Amanda M.} and LaValle, {Taylor A.} and Duncavage, {Eric J.} and Justin Chou and Victor Tam and Benoun, {Joseph M.} and Jenny Nater and Nathalie Scholler and Francesca Milletti and Remus Vezan and Adrian Bot and Rossi, {John M.} and Nathan Singh",

note = "Funding Information: The authors thank the patient, patient{\textquoteright}s family, and caregivers, as well as the study staff at each site. The authors also thank Daved Fremont (Washington University Department of Biochemistry) for guidance with CD19 surface expression studies. Medical writing support was provided by Nexus Global Group Science, funded by Kite, a Gilead Company. Funding Information: Medical writing support was provided by Nexus Global Group Science, funded by Kite, a Gilead Company.",

year = "2022",

month = oct,

day = "25",

doi = "10.1182/bloodadvances.2022007705",

language = "English",

volume = "6",

pages = "5634--5640",

journal = "Blood Advances",

issn = "2473-9529",

number = "20",

}

Ghobadi, A, Landmann, JH, Carter, A, Cooper, ML, Selli, ME, Chang, J, Baker, M, Miller, CA , Ferraro, F, Chen, DY, Smith, AM, LaValle, TA, Duncavage, EJ, Chou, J, Tam, V, Benoun, JM, Nater, J, Scholler, N, Milletti, F, Vezan, R, Bot, A, Rossi, JM & Singh, N 2022, 'Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies', Blood Advances, vol. 6, no. 20, pp. 5634-5640. https://doi.org/10.1182/bloodadvances.2022007705

TY - JOUR

T1 - Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies

AU - Ghobadi, Armin

AU - Landmann, Jack H.

AU - Carter, Alun

AU - Cooper, Matthew L.

AU - Selli, Mehmet Emrah

AU - Chang, Jufang

AU - Baker, Matthew

AU - Miller, Christopher A.

AU - Ferraro, Francesca

AU - Chen, David Y.

AU - Smith, Amanda M.

AU - LaValle, Taylor A.

AU - Duncavage, Eric J.

AU - Chou, Justin

AU - Tam, Victor

AU - Benoun, Joseph M.

AU - Nater, Jenny

AU - Scholler, Nathalie

AU - Milletti, Francesca

AU - Vezan, Remus

AU - Bot, Adrian

AU - Rossi, John M.

AU - Singh, Nathan

N1 - Funding Information: The authors thank the patient, patient’s family, and caregivers, as well as the study staff at each site. The authors also thank Daved Fremont (Washington University Department of Biochemistry) for guidance with CD19 surface expression studies. Medical writing support was provided by Nexus Global Group Science, funded by Kite, a Gilead Company. Funding Information: Medical writing support was provided by Nexus Global Group Science, funded by Kite, a Gilead Company.

PY - 2022/10/25

Y1 - 2022/10/25

UR - http://www.scopus.com/inward/record.url?scp=85141131179&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2022007705

DO - 10.1182/bloodadvances.2022007705

M3 - Letter

C2 - 35858291

AN - SCOPUS:85141131179

SN - 2473-9529

VL - 6

SP - 5634

EP - 5640

JO - Blood Advances

JF - Blood Advances

IS - 20

ER -

Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies

Access to Document

Other files and links

Cite this